<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635541</url>
  </required_header>
  <id_info>
    <org_study_id>YYYY-2018-NAFLD</org_study_id>
    <nct_id>NCT03635541</nct_id>
  </id_info>
  <brief_title>Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an observational study of non alcoholic fatty liver disease (NAFLD) patients with a
      calculated sample size of 90. Liver biopsy proved NAFLD patients will be recruited in this
      study for 2 years follow-up. Patients will be assessed at baseline, at every six months for
      blood count, liver function test, fasting blood-glucose, fasting insulin, ferritin, liver
      ultrasonography, and liver stiffness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>fibrosis progrssion</measure>
    <time_frame>2 years</time_frame>
    <description>dynamic changes in liver stiffness measured by VCTE/MRE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>steatosis progression</measure>
    <time_frame>2 years</time_frame>
    <description>dynamic changes in liver fat measured by controlled attenuation parameter/MRI-PDFF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver related events</measure>
    <time_frame>2 years</time_frame>
    <description>liver decompensation (ascites, variceal bleeding, HE), HCC, liver transplantation, liver relted death.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>observational group of NAFLD</arm_group_label>
    <description>Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational group of NAFLD</intervention_name>
    <description>there's no intervention for patients for it is a observational study</description>
    <arm_group_label>observational group of NAFLD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Non alcoholic fatty liver disease patients diagnosed with liver biopsy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. 18-70 years of age, 2. liver biopsy proven non alcoholic fatty liver disease. 3.
             Agree to be followed up regularly; 4. Signature of written informed consent.

        Exclusion Criteria:

          -  1. Patients with other liver diseases including viral hepatitis, alcoholic liver
             diseases, autoimmune liver diseases, drug induced liver diseases, genetic metabolic
             liver disease.

             2. Patients undergone bariatric surgery. 3. HIV infected patients. 4. Pregnant women.
             5. Patients with severe diseases with expected survival less than 2 years. 6. Patients
             had followings before liver biopsy:

               1. Hepatocellular carcinoma or suspected liver cancer,

               2. Decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal
                  varices bleeding or other complications of decompensated cirrhosis or
                  hepatocelluar carcinoma;

               3. Other malignancy,

               4. Undergone liver transplantation surgery. 7.Patients with any other reasons not
                  suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong You, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong You, Doctor</last_name>
    <phone>861063139019</phone>
    <email>youhong30@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jidong Jia, Doctor</last_name>
    <phone>861063139816</phone>
    <email>jiamd@263.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiwen Shi, Docor</last_name>
      <phone>8601063138665</phone>
      <email>yiwenshi90@163.com</email>
    </contact>
    <investigator>
      <last_name>Hong You, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hong You</investigator_full_name>
    <investigator_title>Vice-Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>non alcoholic fatty liver disease</keyword>
  <keyword>non alcoholic steatohepatitis</keyword>
  <keyword>steatosis</keyword>
  <keyword>fibrosis</keyword>
  <keyword>progression</keyword>
  <keyword>risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

